Published in Circulation on June 11, 2013
Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci Transl Med (2015) 1.25
Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies. J Am Heart Assoc (2014) 1.18
Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst (2014) 0.94
Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovasc Res (2014) 0.87
Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair. Circ Res (2013) 0.84
Vascular Toxicities of Cancer Therapies: The Old and the New - An Evolving Avenue. Circulation (2016) 0.82
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next Level. J Am Coll Cardiol (2015) 0.82
Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions. Angew Chem Int Ed Engl (2014) 0.82
Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury. Br J Pharmacol (2015) 0.81
Complex of C60 Fullerene with Doxorubicin as a Promising Agent in Antitumor Therapy. Nanoscale Res Lett (2015) 0.81
Mechanism-based engineering against anthracycline cardiotoxicity. Circulation (2013) 0.79
Neuregulin as a heart failure therapy and mediator of reverse remodeling. Curr Heart Fail Rep (2014) 0.79
ErbB2 signaling at the crossing between heart failure and cancer. Basic Res Cardiol (2016) 0.79
Neuregulin-1 Administration Protocols Sufficient for Stimulating Cardiac Regeneration in Young Mice Do Not Induce Somatic, Organ, or Neoplastic Growth. PLoS One (2016) 0.78
Sulforaphane prevents doxorubicin-induced oxidative stress and cell death in rat H9c2 cells. Int J Mol Med (2015) 0.76
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells. Mol Pharm (2017) 0.75
Nerve growth factor-induced Akt/mTOR activation protects the ischemic heart via restoring autophagic flux and attenuating ubiquitinated protein accumulation. Oncotarget (2016) 0.75
Comment on "MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction". Oxid Med Cell Longev (2016) 0.75
Ginkgolide B Exerts Cardioprotective Properties against Doxorubicin-Induced Cardiotoxicity by Regulating Reactive Oxygen Species, Akt and Calcium Signaling Pathways In Vitro and In Vivo. PLoS One (2016) 0.75
Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. J Am Heart Assoc (2017) 0.75
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 10.39
Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell (2009) 6.77
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst (2007) 4.14
ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med (2002) 3.36
gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol Cell (2005) 3.24
Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med (2012) 3.20
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci U S A (2010) 2.85
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem (1998) 2.42
Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol (2006) 2.37
Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation (2010) 1.97
Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell (2011) 1.92
Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol (2003) 1.80
Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation (2002) 1.77
Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol (2005) 1.68
Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation (2009) 1.62
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. J Mol Cell Cardiol (2008) 1.46
A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol (2010) 1.40
Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail (2010) 1.39
Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem (2006) 1.36
Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol (2006) 1.35
Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation (2007) 1.35
Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol (2006) 1.33
DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol (2006) 1.28
Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation (2011) 1.10
Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene (1997) 1.00
The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy. Cancer Res (2007) 1.00
Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. Am J Physiol Heart Circ Physiol (2009) 0.98
Roles for neuregulins in human cancer. Clin Exp Metastasis (2004) 0.98
Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells. Cancer Res (2004) 0.98
Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials (2012) 0.97
Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol (2011) 0.96
Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma. Hepatology (2011) 0.94
HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells. Int J Cancer (2009) 0.91
Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem (2011) 0.88
Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med (2007) 8.06
Primary contribution to zebrafish heart regeneration by gata4(+) cardiomyocytes. Nature (2010) 6.69
Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell (2013) 6.35
Stem-cell therapy for cardiac disease. Nature (2008) 5.75
Lamin A/C deficiency causes defective nuclear mechanics and mechanotransduction. J Clin Invest (2004) 5.68
Mammalian heart renewal by pre-existing cardiomyocytes. Nature (2012) 5.56
IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest (2007) 4.31
Bone marrow-derived cell therapy stimulates endogenous cardiomyocyte progenitors and promotes cardiac repair. Cell Stem Cell (2011) 3.49
Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science (2014) 3.37
Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell (2013) 3.35
TXNIP regulates peripheral glucose metabolism in humans. PLoS Med (2007) 3.27
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science (2014) 3.14
Multi-isotope imaging mass spectrometry quantifies stem cell division and metabolism. Nature (2012) 3.04
Lamins A and C but not lamin B1 regulate nuclear mechanics. J Biol Chem (2006) 3.02
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov (2008) 2.90
Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation (2005) 2.89
Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat Chem Biol (2010) 2.87
Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J Clin Invest (2005) 2.80
Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am (2004) 2.79
Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin Chem (2009) 2.77
Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.75
Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol (2005) 2.66
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65
Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation (2003) 2.62
Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation (2003) 2.54
Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation (2004) 2.52
Co-regulation of cell adhesion by nanoscale RGD organization and mechanical stimulus. J Cell Sci (2002) 2.42
Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem (2004) 2.35
Cell mechanics and mechanotransduction: pathways, probes, and physiology. Am J Physiol Cell Physiol (2004) 2.32
Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res (2007) 2.31
FGF1/p38 MAP kinase inhibitor therapy induces cardiomyocyte mitosis, reduces scarring, and rescues function after myocardial infarction. Proc Natl Acad Sci U S A (2006) 2.30
Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction. Circulation (2009) 2.30
Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest (2006) 2.23
Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol (2005) 2.23
The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem (2006) 2.15
Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res (2005) 2.12
The regenerative capacity of zebrafish reverses cardiac failure caused by genetic cardiomyocyte depletion. Development (2011) 2.11
Endothelial cells promote cardiac myocyte survival and spatial reorganization: implications for cardiac regeneration. Circulation (2004) 2.11
Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation (2007) 2.07
Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells (2007) 2.03
Intramyocardial fibroblast myocyte communication. Circ Res (2010) 1.98
Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation (2008) 1.95
Microfluidic shear devices for quantitative analysis of cell adhesion. Anal Chem (2004) 1.95
Perfused multiwell plate for 3D liver tissue engineering. Lab Chip (2009) 1.88
A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng (2002) 1.87
Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. Heart Rhythm (2009) 1.87
Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell (2013) 1.86
Th2-predominant inflammation and blockade of IFN-gamma signaling induce aneurysms in allografted aortas. J Clin Invest (2004) 1.82
Mutation in the transcriptional coactivator EYA4 causes dilated cardiomyopathy and sensorineural hearing loss. Nat Genet (2005) 1.80
Vitamin D(3)-up-regulated protein-1 is a stress-responsive gene that regulates cardiomyocyte viability through interaction with thioredoxin. J Biol Chem (2002) 1.79
Thioredoxin-interacting protein (Txnip) is a critical regulator of hepatic glucose production. J Biol Chem (2007) 1.78
Fluid shear stress inhibits vascular inflammation by decreasing thioredoxin-interacting protein in endothelial cells. J Clin Invest (2005) 1.77
Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail (2009) 1.74
Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem (2009) 1.69
Endothelial-cardiomyocyte interactions in cardiac development and repair. Annu Rev Physiol (2006) 1.68
Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation (2002) 1.67
Epidermal growth factor as a candidate for ex vivo expansion of bone marrow-derived mesenchymal stem cells. Stem Cells (2005) 1.66
Vitamin D3-upregulated protein-1 (VDUP-1) regulates redox-dependent vascular smooth muscle cell proliferation through interaction with thioredoxin. Circ Res (2002) 1.65
Tetraspanin CD151 regulates alpha6beta1 integrin adhesion strengthening. Proc Natl Acad Sci U S A (2003) 1.63
Custom design of the cardiac microenvironment with biomaterials. Circ Res (2005) 1.63
Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. Aging Cell (2008) 1.61
Identification of mechanically induced genes in human monocytic cells by DNA microarrays. J Hypertens (2002) 1.61
Transport-mediated angiogenesis in 3D epithelial coculture. FASEB J (2009) 1.58
Biomechanically induced gene iex-1 inhibits vascular smooth muscle cell proliferation and neointima formation. Circ Res (2003) 1.57
Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem (2012) 1.55
Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. Circulation (2011) 1.55
FGF21 and the late adaptive response to starvation in humans. J Clin Invest (2015) 1.55
Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol (2003) 1.52
High-resolution whole organ imaging using two-photon tissue cytometry. J Biomed Opt (2007) 1.50
Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med (2012) 1.49
Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol (2009) 1.49
A three-dimensional osteochondral composite scaffold for articular cartilage repair. Biomaterials (2002) 1.46
AML1-ETO reprograms hematopoietic cell fate by downregulating scl expression. Development (2008) 1.44
A three-dimensional viscoelastic model for cell deformation with experimental verification. Biophys J (2003) 1.42
Wnt11 patterns a myocardial electrical gradient through regulation of the L-type Ca(2+) channel. Nature (2010) 1.40
Mechanotransduction in cardiac myocytes. Ann N Y Acad Sci (2004) 1.40
Growth factor regulation of proliferation and survival of multipotential stromal cells. Stem Cell Res Ther (2010) 1.39
Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation (2004) 1.37
Cardiomyocyte hypertrophy and degradation of connexin43 through spatially restricted autocrine/paracrine heparin-binding EGF. Proc Natl Acad Sci U S A (2005) 1.36
Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal (2012) 1.36
Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes (2010) 1.36
Rat liver sinusoidal endothelial cells survive without exogenous VEGF in 3D perfused co-cultures with hepatocytes. FASEB J (2007) 1.35
Alpha4beta1 integrin and erythropoietin mediate temporally distinct steps in erythropoiesis: integrins in red cell development. J Cell Biol (2007) 1.35
Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. J Biol Chem (2005) 1.33